Myotonic Dystrophy Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Myotonic Dystrophy pipeline constitutes 20+ key companies continuously working towards developing 22+ Myotonic Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Myotonic Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Myotonic Dystrophy Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myotonic Dystrophy Market.

Get a Free Sample PDF Report to know more about Myotonic Dystrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myotonic-dystrophy-pipeline-insight [https://www.delveinsight.com/report-store/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key takeaways from the Myotonic Dystrophy Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Myotonic Dystrophy treatment therapies with a considerable amount of success over the years.

*
Myotonic Dystrophy companies working in the treatment market are EditForce, Inc., Arrowhead Pharmaceuticals, Inc., Vertex Pharmaceuticals, Pepgen Corporation, Avidity Biosciences, Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma, Dyne Therapeutics, Entrada Therapeutics, and others, are developing therapies for the Myotonic Dystrophy treatment

*
Emerging Myotonic Dystrophy therapies in the different phases of clinical trials are- EF-210, ARO-DM1, VX-670, PGN-EDODM1, Delpacibart etedesiran, DM1 program, ENZ-001, JUV 161, DYNE-101, AOC 1001, Pitolisant, Tideglusib, Mexiletine, AMO-02, DYNE-101, ENTR-701, and others are expected to have a significant impact on the Myotonic Dystrophy market in the coming years.

*
In June 2026, Dyne Therapeutics has completed enrollment in the registrational expansion cohort of the Phase I/II ACHIEVE trial evaluating zeleciment basivarsen (z-basivarsen/DYNE-101) for patients with myotonic dystrophy type 1 (DM1). The cohort enrolled 71 participants, with topline results anticipated in the first quarter of 2027 to support a potential U.S. Accelerated Approval submission later that year. The ACHIEVE study is assessing the safety and efficacy of z-basivarsen, an investigational therapy designed to address the underlying genetic cause of DM1. Pending positive results and regulatory approvals, Dyne aims to launch the therapy in the U.S. by mid-2028 while also pursuing commercialization in international markets.

*
In March 2026, The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 trial due to concerns related to certain preclinical pharmacology and toxicology studies. The Phase 2 trial is designed as a multiple ascending dose study evaluating PGN-EDODM1 in patients with Myotonic Dystrophy Type 1 (DM1). Importantly, the partial hold does not involve any issues with the blinded clinical data from the earlier Phase 1 FREEDOM study, which had previously been submitted to support the initiation of the FREEDOM2 trial in the United States. As part of ongoing discussions with the FDA, PepGen is providing additional analyses, including newly unblinded data from the FREEDOM study.

*
In February 2026, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company focused on developing a novel class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs Trademark ), announced that the final findings from the completed Phase 1/2 MARINA Registered clinical trial evaluating delpacibart etedesiran (del-desiran) in patients with Myotonic Dystrophy Type 1 will be published in the February 19 edition of The New England Journal of Medicine. The research article is titled "An Antibody Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

*
In June 2025, Dyne Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to DYNE-101 for treating myotonic dystrophy type 1 (DM1). The company also shared an updated strategy for pursuing US Accelerated Approval for DYNE-101 in DM1, following a Type C meeting with the FDA and the review of new long-term functional data.

*
In April 2025, Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs Trademark ), announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to delpacibart etedesiran (del-desiran) for treating myotonic dystrophy type 1 (DM1). Del-desiran, an investigational therapy targeting the root cause of DM1-a progressive, often fatal neuromuscular disease with no approved treatments-is the first DM1 therapy to receive ODD in Japan. The drug has also received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the U.S. FDA, as well as Orphan designation from the European Medicines Agency (EMA).

*
In April 2025, Avidity Biosciences, Inc. announced that delpacibart etedesiran (del-desiran) has received Orphan Drug Designation (ODD) from Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of myotonic dystrophy type 1 (DM1).

*
In February 2025, PepGen Inc. reported encouraging initial clinical results from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase I trial evaluating PGN-EDODM1 for the treatment of myotonic dystrophy type 1 (DM1).

Myotonic Dystrophy Overview

The most prevalent form of muscular dystrophy that manifests in adulthood is myotonic dystrophy (DM), which is regarded as a subtype of myopathy. Myotonic dystrophy type I (DM1), also known as Steinert disease, and myotonic dystrophy type II (DM2), also known as proximal myotonic myopathy, which is a milder form of DMI, are the two main forms recognised based on clinical and molecular presentation.

Explore the latest Myotonic Dystrophy pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Myotonic Dystrophy Clinical Trials [https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Myotonic Dystrophy Drugs Under Different Phases of Clinical Development Include:

*
EF-210: EditForce, Inc.

*
ARO-DM1: Arrowhead Pharmaceuticals, Inc.

*
VX-670: Vertex Pharmaceuticals

*
PGN-EDODM1: Pepgen Corporation

*
Delpacibart etedesiran: Avidity Biosciences

*
DM1 program: Design Therapeutics

*
ENZ-001: Enzerna

*
JUV 161: Juvena Therapeutics

*
DYNE-101: Dyne Therapeutics

*
AOC 1001: Avidity Biosciences

*
Pitolisant: Harmony Biosciences

*
Tideglusib: AMO Pharma

*
Mexiletine: Lupin

*
AMO-02: AMO Pharma

*
DYNE-101: Dyne Therapeutics

*
ENTR-701: Entrada Therapeutics

Myotonic Dystrophy Route of Administration

Myotonic Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Myotonic Dystrophy Molecule Type

Myotonic Dystrophy Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Myotonic Dystrophy Pipeline Therapeutics Assessment

*
Myotonic Dystrophy Assessment by Product Type

*
Myotonic Dystrophy By Stage and Product Type

*
Myotonic Dystrophy Assessment by Route of Administration

*
Myotonic Dystrophy By Stage and Route of Administration

*
Myotonic Dystrophy Assessment by Molecule Type

*
Myotonic Dystrophy by Stage and Molecule Type

DelveInsight's Myotonic Dystrophy Report covers around 22+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Myotonic Dystrophy product details are provided in the report. Download the Myotonic Dystrophy pipeline report to learn more about the emerging Myotonic Dystrophy therapies [https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Myotonic Dystrophy Therapeutics Market include:

Key companies developing therapies for Myotonic Dystrophy are - Lupin, AMO Pharma, Harmony Biosciences, Avidity Biosciences, Dyne Therapeutics, Nexien BioPharma, Locana, Inc., Entrada Therapeutics, Arthex Biotech, NeuBase Therapeutics, NeuBase Therapeutics, Enzerna, Enzerna, Astellas Gene Therapies, Dyne Therapeutics, Pepgen Corporation, Sangamo Therapeutics, Syros Pharmaceuticals, and others.

Myotonic Dystrophy Pipeline Analysis:

The Myotonic Dystrophy pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Myotonic Dystrophy with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myotonic Dystrophy Treatment.

*
Myotonic Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Myotonic Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myotonic Dystrophy market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myotonic Dystrophy drugs and therapies [https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Myotonic Dystrophy Pipeline Market Drivers

*
Technological advancements in Myotonic Dystrophy genomic research, management of multisystem disorder associated with Myotonic Dystrophy are some of the important factors that are fueling the Myotonic Dystrophy Market.

Myotonic Dystrophy Pipeline Market Barriers

*
However, lack of Approved therapies, lack of understanding of pathophysiology and mechanisms of DNA instability and other factors are creating obstacles in the Myotonic Dystrophy Market growth.

Scope of Myotonic Dystrophy Pipeline Drug Insight

*
Coverage: Global

*
Key Myotonic Dystrophy Companies: EditForce, Inc., Arrowhead Pharmaceuticals, Inc., Vertex Pharmaceuticals, Pepgen Corporation, Avidity Biosciences, Design Therapeutics, Enzerna, Juvena Therapeutics, Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin, AMO Pharma, Dyne Therapeutics, Entrada Therapeutics, and others

*
Key Myotonic Dystrophy Therapies: EF-210, ARO-DM1, VX-670, PGN-EDODM1, Delpacibart etedesiran, DM1 program, ENZ-001, JUV 161, DYNE-101, AOC 1001, Pitolisant, Tideglusib, Mexiletine, AMO-02, DYNE-101, ENTR-701, and others

*
Myotonic Dystrophy Therapeutic Assessment: Myotonic Dystrophy current marketed and Myotonic Dystrophy emerging therapies

*
Myotonic Dystrophy Market Dynamics: Myotonic Dystrophy market drivers and Myotonic Dystrophy market barriers

Request for Sample PDF Report for Myotonic Dystrophy Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/myotonic-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Myotonic Dystrophy Report Introduction

2. Myotonic Dystrophy Executive Summary

3. Myotonic Dystrophy Overview

4. Myotonic Dystrophy- Analytical Perspective In-depth Commercial Assessment

5. Myotonic Dystrophy Pipeline Therapeutics

6. Myotonic Dystrophy Late Stage Products (Phase II/III)

7. Myotonic Dystrophy Mid Stage Products (Phase II)

8. Myotonic Dystrophy Early Stage Products (Phase I)

9. Myotonic Dystrophy Preclinical Stage Products

10. Myotonic Dystrophy Therapeutics Assessment

11. Myotonic Dystrophy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myotonic Dystrophy Key Companies

14. Myotonic Dystrophy Key Products

15. Myotonic Dystrophy Unmet Needs

16 . Myotonic Dystrophy Market Drivers and Barriers

17. Myotonic Dystrophy Future Perspectives and Conclusion

18. Myotonic Dystrophy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myotonic-dystrophy-pipeline-2026-key-companies-moa-roa-and-clinical-trials-evaluation-by-delveinsight-dyne-therapeutics-avidity-biosciences-harmony-biosciences-amo-pharma-lupin-amo-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.